Tumour-targeted fluorescence-guided surgery (Ttfgs) enhances intraoperative precision in gastrointestinal cancer treatment. Translation of (Ttfgs) into clinical practice is limited by heterogeneity, regulatory hurdles, biomarker variability and absence of phase III trials. Innovations such as multimodal tracers and theranostic agents may further enhance the precision and therapeutic potential of Ttfgs.
Darai et al. (Sun,) studied this question.